Rebecca Z. Rousset

Rebecca Z. Rousset

Auto-generated profile, based on publicly available information

Rebecca Z. Rousset

Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in BMJ
Verified
Journal Article
Open access
PDF file
VJValentijn de Jong
Valentijn de Jong
RRRebecca Z Rousset
Rebecca Z Rousset
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
ABArnoldus G Buenen
Arnoldus G Buenen
BCBen Van Calster
Ben Van Calster
TDThomas P. Debray
Thomas P. Debray
Objective: To externally validate various prognostic models and scoring rules for predicting short term mortality in patients admitted to hospital for covid-19. Design: Two stage individual participant data meta-analysis. Setting: Secondary and tertiary care. Participants: 46 914 patients across 18 countries, admitted to a hospital with polymerase chain reaction confirmed covid-19 from November 2019 to April 2021. Data sources: Multiple (clustered) cohorts in Brazil, Belgium, China, Czech Republic, Egypt, France, Iran, Israel, Italy, Mexico, Netherlands, Portugal, Russia, Saudi Arabia, Spain, Sweden, United Kingdom, and United States previously identified by a living systematic review of covid-19 prediction models published in The BMJ , and through PROSPERO, reference checking, and expert knowledge. Model selection and eligibility criteria: Prognostic models identified by the living systematic review and through contacting experts. A priori models were excluded that had a high risk of bias in the participant domain of PROBAST (prediction model study risk of bias assessment tool) or for which the applicability was deemed poor. Methods: Eight prognostic models with diverse predictors were identified and validated. A two stage individual participant data meta-analysis was performed of the estimated model concordance (C) statistic, calibration slope, calibration-in-the-large, and observed to expected ratio (O:E) across the included clusters. Main outcome measures: 30 day mortality or in-hospital mortality. Results: Datasets included 27 clusters from 18 different countries and contained data on 46 914patients. The pooled estimates ranged from 0.67 to 0.80 (C statistic), 0.22 to 1.22 (calibration slope), and 0.18 to 2.59 (O:E ratio) and were prone to substantial between study heterogeneity. The 4C Mortality Score by Knight et al (pooled C statistic 0.80, 95% confidence interval 0.75 to 0.84, 95% prediction interval 0.72 to 0.86) and clinical model by Wang et al (0.77, 0.73 to 0.80, 0.63 to 0.87) had the highest discriminative ability. On average, 29% fewer deaths were observed than predicted by the 4C Mortality Score (pooled O:E 0.71, 95% confidence interval 0.45 to 1.11, 95% prediction interval 0.21 to 2.39), 35% fewer than predicted by the Wang clinical model (0.65, 0.52 to 0.82, 0.23 to 1.89), and 4% fewer than predicted by Xie et al’s model (0.96, 0.59 to 1.55, 0.21 to 4.28). Conclusion: The prognostic value of the included models varied greatly between the data sources. Although the Knight 4C Mortality Score and Wang clinical model appeared most promising, recalibration (intercept and slope updates) is needed before implementation in routine care.

1 October 2024 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
PDF file
RRRebecca Z. Rousset
Rebecca Z. Rousset
TCThomas Claessen
Thomas Claessen
AHArgonde C. van Harten
Argonde C. van Harten
ALAfina W. Lemstra
Afina W. Lemstra
YPYolande A. L. Pijnenburg
Yolande A. L. Pijnenburg
CTCharlotte E. Teunissen
Charlotte E. Teunissen
INTRODUCTION: Plasma phosphorylated tau‐217 (p‐tau217) and neurofilament light (NfL) can differentiate between different dementias in selected cohorts. We aim to test the discrimination potential of these markers in a real‐world cohort.METHODS: We measured p‐tau217 (ALZpath) and NfL (Quanterix) in 415 (unselected) consecutive memory clinic patients. Biomarker levels were dichotomized as low/high to create four biomarker profiles based on p‐tau217 and NfL levels.RESULTS: p‐Tau217 levels were highest in patients with Alzheimer's disease (AD) dementia, whereas NfL levels were highest in patients with frontotemporal dementia (FTD). Low p‐tau217/low NfL was associated mostly with non‐neurological diagnoses (79%), and high p‐tau217/low NfL indicated AD pathology at any stage (84%). Low p‐tau217/high NfL indicated FTD (38%) and high p‐tau217/high NfL indicated AD dementia (87%).DISCUSSION: p‐Tau217 can identify AD pathology at any disease stage. NfL can differentiate FTD from other diagnoses (e.g., AD dementia). Plasma p‐tau217 and NfL can support clinical decision‐making, and we suggest using them as complements to standard clinical assessment.Highlights: Phosphorylated tau‐2017 (p‐tau217) can detect Alzheimer's disease (AD) across the clinical continuum. Neurofilament light (NfL) can differentiate frontotemporal dementia (FTD) from other diagnoses (AD dementia, dementia with Lewy bodies [DLB], and Psychiatry). p‐Tau217 may detect AD co‐pathology in other diseases or dementia types (e.g., DLB). p‐Tau217 and NfL show potential for clinical implementation.

26 November 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
RRRebecca Z. Rousset
Rebecca Z. Rousset
ABAnouk Den Braber
Anouk Den Braber
IVInge M. W. Verberk
Inge M. W. Verberk
LBLynn Boonkamp
Lynn Boonkamp
DWDavid H. Wilson
David H. Wilson
EGEco J. C. de Geus
Eco J. C. de Geus
INTRODUCTION: Alzheimer's disease (AD) is a highly heritable disease (60%–80%). Amyloid beta (Aβ) 42/40, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) are plasma biomarkers for AD. Clinical biomarker research would be served by an understanding of the sources of variance in these markers. METHODS: Blood concentrations of Aβ42/40, NfL, and GFAP of twins and their families (monozygotic twins: 1574, dizygotic twins: 1266, other: 3657) were analyzed on the Simoa HD‐X. Twin‐family models were used to estimate proportional genetic contributions to the variance in biomarker levels. RESULTS: Heritability estimates were 16% for Aβ42/40, 42% for NfL, and 60% for GFAP. NfL and GFAP were significantly correlated with each other (0.37) but not with Aβ42/40. DISCUSSION: The heritability of Aβ42/40 (16%) is lower than the heritability of AD, suggesting strong environmental influences on this biomarker. The lack of correlation between NfL/GFAP and Aβ42/40 indicates these markers may be on different biological pathways. Highlights: Heritability is found for glial fibrillary acidic protein (60%), neurofilament light chain (42%), and amyloid beta (Aβ) 42/40 (16%) plasma levels. Aβ42/40 plasma levels are sensitive to person‐specific environmental influences.

1 May 2026 in JAMA Network Open
Verified
Journal Article
Open access
RRRebecca Z. Rousset
Rebecca Z. Rousset
MHMadison I. J. Honey
Madison I. J. Honey
ABAnouk Den Braber
Anouk Den Braber
WFWiesje M. van der Flier
Wiesje M. van der Flier
HHHenne Holstege
Henne Holstege
CTCharlotte E. Teunissen
Charlotte E. Teunissen
Importance: Concentrations of plasma neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) should be easily interpretable in the context of a patient’s profile. Objectives: To develop reference intervals (RI) for NfL and GFAP, accounting for common physiological modifiers of biomarkers and to compare these RIs with concentrations from participants with neurological conditions. Design, Setting, and Participants: This cross-sectional study included participants with no cognitive impairment (self-reported, assessed by Mini-Mental State Examination score ≥27, or determined by a physician) to generate and validate the RIs as well as individuals, recruited from tertiary clinics, with subjective cognitive decline or mild cognitive impairment due to Alzheimer disease (AD), AD dementia, frontotemporal dementia (FTD), dementia with Lewy bodies, vascular dementia (VaD), or multiple sclerosis, for the comparison group. Exposures: Age, biological sex (self-reported), body mass index (BMI), and kidney function (measured by estimated glomerular filtration rate [eGFR]). Main Outcomes and Measures: Plasma NfL and GFAP RIs, quantified on the Simoa HD-X, defined over age and adjusted for sex, BMI, and/or eGFR. Results: In 7989 cognitively unimpaired participants (median [range] age, 54 [30-90] years; 4877 [61.3%] female; mean [SD] BMI, 25.9 [4.2]; mean [SD] eGFR, 80.7 [14.7] mL/min/1.73 m 2 ), older age, lower BMI, and reduced kidney function were associated with increased NfL and GFAP concentrations; female sex was associated with increased GFAP concentrations. Median NfL and GFAP concentrations were 6.58 (6.58-6.58) pg/mL and 23.4 (23.4-23.4) pg/mL higher, respectively, in participants with severe compared with no kidney damage (ie, 45 mL/min/1.73 m 2 vs 90 mL/min/1.73 m 2 ). Median NfL and GFAP concentrations were 1.72 (1.72-1.72) pg/mL and 12.6 (12.6-12.6) pg/mL lower, respectively, in participants with obesity compared with those with normal weight (ie, BMI of 30 vs 20). Median GFAP concentrations were 6.17 (6.17-6.17) pg/mL higher in female compared with male participants. NfL concentrations were most elevated in participants with FTD (165 of 179 participants [92.2%] had concentrations greater than the median) and VaD (55 of 60 participants [91.7%] had concentrations greater than the median). GFAP concentrations were most elevated in participants with AD dementia (396 of 479 participants [82.7%] had concentrations greater than the median). A user-friendly interface was developed to visualize the biomarker RIs in the context of an individual’s age, BMI, eGFR, and sex. Conclusions and Relevance: In this cross-sectional study of 7958 individuals, RIs to identify normal or abnormal biomarker concentrations in the context of a cognitively unimpaired individuals were established to aid the use of plasma NfL and GFAP measures in clinical practice for neurological diseases.

13 November 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
RRRebecca Z. Rousset
Rebecca Z. Rousset
CDConor V. Dolan
Conor V. Dolan
DWDavid H. Wilson
David H. Wilson
LVLisanne In ‘t Veld
Lisanne In ‘t Veld
LLLannie Ligthart
Lannie Ligthart
ABAnouk Den Braber
Anouk Den Braber
INTRODUCTION: Plasma phosphorylated tau 217 (p‐au217) is a promising Alzheimer's disease (AD) biomarker. Little is known about the causes of variance in p‐tau217 concentrations in cognitively unimpaired populations. METHODS: The present sample included cognitively healthy twins and their family members ( n = 6495). Biometric twin models were used to determine relative genetic and environmental contributions to variance in p‐tau217, and genetic and environmental correlations between p‐tau217 and neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and amyloid beta 42/40 (Aβ42/40). RESULTS: Genetic contributions accounted for 42% (males) and 41% (females) of variance in p‐tau217. Half of the genetic effects were sex specific. Genetic and environmental contributions to p‐tau217 were partially shared with NfL, GFAP, and Aβ42/40, but different patterns were found in males and females. DISCUSSION: P‐tau217 concentrations are moderately heritable. Sex‐specific genetic influences are found to act on p‐tau217. In cognitively unimpaired participants, p‐tau217 and Aβ42/40 reflect different biological processes. Highlights: Phosphorylated tau (p‐tau)217 concentrations are substantially heritable (> 41%). Genetic contributions to variation in plasma p‐tau217 were found to be sex specific. Genetic and environmental correlations were found between p‐tau217 and Alzheimer's disease biomarkers. P‐tau217 reflects different processes in cognitively unimpaired males and females.

17 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RRRebecca Z. Rousset
Rebecca Z. Rousset
ABAnouk Den Braber
Anouk Den Braber
BBBram Bongers
Bram Bongers
LBLynn Boonkamp
Lynn Boonkamp
DWDavid Wilson
David Wilson
CTCharlotte E. Teunissen
Charlotte E. Teunissen
Alzheimer’s disease (AD) plasma biomarkers are cost-effective tools to detect early stage amyloid pathology. We investigated how interactions between AD genetic risk (apolipoprotein E (APOE) ε4, AD polygenic risk score (excluding APOE; PRSAD)), age, and sex affected AD plasma biomarkers concentrations in a population-based cohort. We included 5913 participants from the Netherlands Twin Register age 30 – 80 (64.1% females, 29.8% ε4 carriers) and measured plasma phosphorylated-tau-217 (p-tau217), amyloid-β−42/40 (Aβ−42/40), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). We showed that the PRSAD did not associate with biomarker concentrations over age. In ε4 carriers, decreases in Aβ−42/40 became steeper after age 50, and increases in p-tau217 and GFAP became steeper after age 55 and 60 compared to non-carriers, respectively. Analyses in a separate longitudinal cohort (EMIF-AD) confirmed that p-tau217 concentration changes in ε4 carriers reflect AD pathology. These results highlight the potential of plasma biomarkers, especially p-tau217, for early detection of preclinical AD pathology.